title: Serum tumor markers in hemodialysis patients.
abstract: OBJECTIVE
  The main objective of this work was to evaluate the influence of end-stage renal disease (ESRD) on concentrations of five tumor markers (TMs): carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9 (CA19-9), CA15-3, CA125, and prostate specific antigen (PSA) in a group of chronic hemodialysis patients (CHPs); and to study the influence of hemodialysis (HD) sessions on concentrations of the same TMs.
  
  
  METHODS
  We compared TMs levels in CHP before HD sessions to a control group of 50 healthy volunteers, the dosages were determined before and immediately after the HD session Comparisons were made before and after correction for dialysis-induced hemoconcentrations.
  
  
  RESULTS
  We enrolled 74 CHPs, all TM concentrations were higher in this group compared to control group, but this increase was significant for CEA (4.25 ± 2.89 vs 2.41 ± 1.81ng/ml; p<0.0001), CA125 (27.84 ± 92.27 vs 13.30 ± 9.85 ng/ml; p = 0.048) and CA19-9 (19.65 ± 25.02 vs 10.23 ± 11.00 U/ml; p = 0.011). Post-dialysis levels were significantly higher than those in pre-dialysis. CEA (3.35 [2,46-5.51] vs 4,06 [2.60-6.78] ng/ml; p<0.0001), CA125 (13.24 [9.66-18.63] vs 16.01 [11.33-22.53] ng/ml; p<0.0001), CA19-9 (12.29 [5.59-21.97] vs 16.29 [7.18-24.7] U/ml; p<0.0001), CA15-3 (13.06 [10.05-17.48] vs 14.58 [11.72-19.35] ng/ml; p<0.0001 and PSA (0.83 [0.5-1.24] vs 1.06 [0.62-1.43] ng/ml; p<0.0001).
  
  
  CONCLUSIONS
  Our work confirms that HD increases concentrations of the five TMs evaluated and suggests that the use of CA15-3 and PSA remains valid in CHPs since their concentrations were not altered by ESRD, unlike CEA, CA125, and CA19-9.
authors.affiliation: 1 Department of Nephrology and Dialysis, 1st Medical and surgical Military Hospital, Agadir - Morocco.
authors.forename: Omar
authors.initials: O
authors.lastname: Maoujoud
authors.forename: Samira
authors.initials: S
authors.lastname: El Machtani
authors.forename: Mohammed
authors.initials: M
authors.lastname: Asseraji
authors.forename: Yassine
authors.initials: Y
authors.lastname: Atbib
authors.forename: Yassir
authors.initials: Y
authors.lastname: Zajjari
authors.forename: Aatif
authors.initials: A
authors.lastname: Taoufik
authors.forename: Elarabi
authors.initials: E
authors.lastname: Elbouaiti
authors.forename: Oualim
authors.initials: O
authors.lastname: Zouhair
authors.forename: Mohammed
authors.initials: M
authors.lastname: Benyahia
authors.forename: Saida
authors.initials: S
authors.lastname: Tellal
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis / Q000097:blood; D018394:CA-125 Antigen / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood*; D017430:Prostate-Specific Antigen / Q000097:blood*; D006435:Renal Dialysis / Q000379:methods*; D015203:Reproducibility of Results
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D018396:Mucin-1; D017430:Prostate-Specific Antigen